Head-To-Head Survey: Avalon GloboCare (NASDAQ:ALBT) versus Brainstorm Cell Therapeutics (NASDAQ:BCLI)

Avalon GloboCare (NASDAQ:ALBT) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk and valuation.

Volatility & Risk

Avalon GloboCare has a beta of 0.27, indicating that its stock price is 73% less volatile than the S&P 500. Comparatively, Brainstorm Cell Therapeutics has a beta of 0.36, indicating that its stock price is 64% less volatile than the S&P 500.

Valuation & Earnings

This table compares Avalon GloboCare and Brainstorm Cell Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalon GloboCare	$1.26 million	2.06	-$16.71 million	($19.96)	-0.12
Brainstorm Cell Therapeutics	N/A	N/A	-$17.19 million	($4.80)	-0.36

Avalon GloboCare has higher revenue and earnings than Brainstorm Cell Therapeutics. Brainstorm Cell Therapeutics is trading at a lower price-to-earnings ratio than Avalon GloboCare, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations for Avalon GloboCare and Brainstorm Cell Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalon GloboCare	0	0	0	0	0.00
Brainstorm Cell Therapeutics	0	0	1	0	3.00

Brainstorm Cell Therapeutics has a consensus price target of $30.00, indicating a potential upside of 1,634.10%. Given Brainstorm Cell Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Brainstorm Cell Therapeutics is more favorable than Avalon GloboCare.

Institutional and Insider Ownership

1.4% of Avalon GloboCare shares are owned by institutional investors. Comparatively, 14.3% of Brainstorm Cell Therapeutics shares are owned by institutional investors. 37.3% of Avalon GloboCare shares are owned by insiders. Comparatively, 6.7% of Brainstorm Cell Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Avalon GloboCare and Brainstorm Cell Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Avalon GloboCare	-1,125.59%	N/A	-73.69%
Brainstorm Cell Therapeutics	N/A	N/A	-528.56%

Summary

Brainstorm Cell Therapeutics beats Avalon GloboCare on 7 of the 11 factors compared between the two stocks.

About Avalon GloboCare

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing mRNA-based Flash-CAR cell therapy platform. In addition, the company develops Avalon clinical-grade tissue-specific exosome (ACTEX); AVA-Trap, a therapeutic program provides an effective therapeutic option to combat COVID-19 and other life-threatening conditions involving cytokine storms; offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Avalon GloboCare Corp. has strategic partnership with HydroPeptide, LLC to engage in co-development and commercialization of a series of clinical-grade, exosome-based cosmeceutical, and orthopedic products; and corporate research agreement with the University of Pittsburgh of the Commonwealth System of Higher Education. The company was founded in 2016 and is headquartered in Freehold, New Jersey.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.